Endpoints News
Parabilis plots $413M IPO Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Thu F
4 June, 2026
LGBTQ+ LEADERSHIP IN 2026
LGBTQ+ diversity drives innovation in biopharma — but transgender and non-binary professionals face rising challenges. Endpoints is going live with our fourth annual special report celebrating the honorees giving voice and visibility while forging ahead across life sciences. Join us.
top stories
1. Germany’s health-spending plan has consequences as Lilly, Boehringer scale back
2. Parabilis Medicines charts $413M IPO to back peptide pipeline
3.
news briefing
Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic
4. ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
5. Alnylam signs its first AI discovery deal with RNA specialist Inceptive
6. ADC biotech Ona Therapeutics secures $86.6M in Series B raise
7. Explaining unapproved drugs to payors: FDA offers pharma new guidance to avoid pitfalls
8. Axsome pushes back generic entry for narcolepsy drug until 2040
more stories
• 
Karen Weintraub
.

The German government has proposed dramatic cuts to its spending on drugs. As Ayisha Sharma explains, Eli Lilly and Boehringer Ingelheim are adding to a growing chorus that's fighting back.
.
Karen Weintraub
Deputy Editor, Endpoints News
1
by Ayisha Sharma

Back­lash is brew­ing against a sweep­ing over­haul of Ger­many’s health in­sur­ance sys­tem as Eli Lil­ly and Boehringer In­gel­heim slash in­vest­ment in the coun­try.

The drug­mak­er­s'...

Read full story
Mathai Mammen, Parabilis Medicines CEO (via Sandoz)
2
by Kyle LaHucik

Para­bilis Med­i­cines, the pep­tide biotech led by for­mer John­son & John­son R&D head Math­ai Mam­men, is seek­ing more than $400 mil­lion in its Nas­daq de­but...

Read full story
News Briefing: Quick hits from the biopharma web
3
by ENDPOINTS

Plus news about IMU Bio­sciences, Au­to­bahn and Jade Bio­sciences.

💸 No­vo Hold­ings in­vests in Eu­rope-fo­cused fund: The in­vest­ment man­ag­er of the No­vo Nordisk Foun­da­tion's for­tunes...

Read full story
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
4
by Reynald Castaneda

ADC Ther­a­peu­tics’ bid to se­cure full ap­proval for Zyn­lon­ta in re­lapsed or re­frac­to­ry dif­fuse large B-cell lym­phoma has been com­pli­cat­ed by death rates in its...

Read full story
5
by Andrew Dunn

Al­ny­lam Phar­ma­ceu­ti­cals an­nounced its first dis­cov­ery-fo­cused AI deal Wednes­day, tap­ping a Sil­i­con Val­ley biotech start­up to see if AI can boost its R&D ef­forts.

Al­ny­lam and...

Read full story
Valerie Vanhooren, Ona Therapeutics CEO
6